Belize vs Eastern Mediterranean (WHO region): Treatment success rate for patients treated for MDR-TB
Belize
100.0%
in 2022
Eastern Mediterranean (WHO region)
75.0%
in 2022
Belize rank
1st
Eastern Mediterranean (WHO region) rank
4th
Treatment success rate for patients treated for MDR-TB over time
- Belize
- Eastern Mediterranean (WHO region)
How they compare
Belize currently reports 100.0% against 75.0% in Eastern Mediterranean (WHO region), a difference of 25.0%.
That makes Belize's figure about 1.3 times Eastern Mediterranean (WHO region)'s.
The two have swapped places 4 times across 8 shared years of data; in 2009 it was Belize ahead.
Belize ranks 1st and Eastern Mediterranean (WHO region) ranks 4th of 163 countries.
Across the 3 decades both report, Belize averaged higher in 2 and Eastern Mediterranean (WHO region) in 1.
Head to head by decade
| Decade | Belize | Eastern Mediterranean (WHO region) | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 100.0% | 44.0% | 56.0% | Belize |
| 2010s | 87.5% | 65.8% | 21.8% | Belize |
| 2020s | 66.7% | 74.0% | 7.3% | Eastern Mediterranean (WHO region) |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher treatment success rate for patients treated for mdr-tb, Belize or Eastern Mediterranean (WHO region)?
- Belize, at 100.0% against 75.0% in Eastern Mediterranean (WHO region) as of 2022.
- What is the difference in treatment success rate for patients treated for mdr-tb between Belize and Eastern Mediterranean (WHO region)?
- 25.0%, with Belize ahead.
- How many years of comparable data are there for Belize and Eastern Mediterranean (WHO region)?
- 8 years are reported by both, from 2009 to 2022.
- How do Belize and Eastern Mediterranean (WHO region) rank globally for treatment success rate for patients treated for mdr-tb?
- Belize ranks 1st and Eastern Mediterranean (WHO region) ranks 4th of 163 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Treatment success rate for patients treated for MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.